ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:ULUR
- CUSIP: N/A
- Web: www.uluruinc.com
Capitalization:- Market Cap: $5.12 million
- Outstanding Shares: 76,349,000
Average Prices:- 50 Day Moving Avg: $0.07
- 200 Day Moving Avg: $0.07
- 52 Week Range: $0.03 - $0.30
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $550,890.00
- Price / Sales: 9.29
- Book Value: $0.10 per share
- Price / Book: 0.68
Profitability:- EBIDTA: ($1,310,000.00)
- Net Margins: -774.96%
- Return on Equity: -93.95%
- Return on Assets: -58.63%
Debt:- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 2.64%
- Quick Ratio: 2.42%
Misc:- Average Volume: 9,238 shs.
- Beta: 1.32
- Short Ratio: 0.08
Frequently Asked Questions for ULURU (OTCMKTS:ULUR)
What is ULURU's stock symbol?
ULURU trades on the OTCMKTS under the ticker symbol "ULUR."
How were ULURU's earnings last quarter?
ULURU Inc. (OTCMKTS:ULUR) announced its earnings results on Monday, November, 17th. The company reported ($0.03) EPS for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.02. The business had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.70 million. ULURU had a negative net margin of 774.96% and a negative return on equity of 93.95%. During the same period in the prior year, the company posted ($0.05) earnings per share. View ULURU's Earnings History.
Who are some of ULURU's key competitors?
Some companies that are related to ULURU include Bio Blast Pharma (ORPN), Valeritas Holdings (VLRX), Relmada Therapeutics (RLMDD), Mateon Therapeutics (MATN), Dipexium Pharmaceuticals (PLXP), Celsion Corporation (CLSN), Ritter Pharmaceuticals (RTTR), Opexa Therapeutics (OPXA), Acura Pharmaceuticals (ACUR), Rosetta Genomics (ROSG), Kitov Pharmaceuticals Holdings (KTOV), Strata Skin Sciences (SSKN), NeuroMetrix (NURO), Windtree Therapeutics (WINT), Critical Outcome T (COTQF), Affymax (AFFY), Adeptus Health (ADPT) and Bayer AG (BAYRY).
Who are ULURU's key executives?
ULURU's management team includes the folowing people:
- Bradley J. Sacks, Chairman of the Board
- Vaidehi Shah, Chief Executive Officer, Director
- Terrance K. Wallberg, Chief Financial Officer, Vice President, Treasurer, Secretary, Director
- Arindam Bose, Director
How do I buy ULURU stock?
Shares of ULURU can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ULURU's stock price today?
One share of ULURU stock can currently be purchased for approximately $0.07.
MarketBeat Community Rating for ULURU (OTCMKTS ULUR)MarketBeat's community ratings are surveys of what our community members think about ULURU and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ULURU (OTCMKTS:ULUR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for ULURU (OTCMKTS:ULUR)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for ULURU (OTCMKTS:ULUR)Earnings History by Quarter for ULURU (OTCMKTS ULUR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/1/2015 | | | $0.01 | $0.45 million | $0.23 million | View | N/A |  |
| 11/17/2014 | Q3 14 | ($0.01) | ($0.03) | $0.70 million | $0.32 million | View | N/A | |
| 8/15/2014 | | ($0.02) | ($0.03) | $0.43 million | $0.21 million | View | N/A | |
| 4/2/2014 | | ($0.04) | ($0.04) | | | View | N/A | |
| 4/1/2014 | Q4 13 | | ($0.04) | $0.14 million | $0.13 million | View | N/A | |
| 11/15/2013 | Q3 13 | ($0.06) | ($0.05) | | | View | N/A | |
| 8/15/2013 | Q2 2013 | | ($0.06) | $0.06 million | $0.03 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ULURU (OTCMKTS:ULUR)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ULURU (OTCMKTS:ULUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ULURU (OTCMKTS:ULUR)Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 0.03%
Insider Trades by Quarter for ULURU (OTCMKTS:ULUR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/29/2016 | Bradley J Sacks | Insider | Buy | 266,480 | $0.07 | $18,653.60 | |
| 3/29/2016 | Terrance K Wallberg | CFO | Buy | 701,262 | $0.07 | $49,088.34 | |
| 1/6/2014 | Gmbh Ipmd | Major Shareholder | Buy | 1,250,000 | $0.40 | $500,000.00 | |
| 10/24/2013 | Gmbh Ipmd | Major Shareholder | Buy | 750,000 | $0.40 | $300,000.00 | |
| 9/6/2013 | Gmbh Ipmd | Major Shareholder | Buy | 750,000 | $0.40 | $300,000.00 | |
| 5/7/2013 | Gmbh Ipmd | Major Shareholder | Buy | 1,250,000 | $0.40 | $500,000.00 | |
| 3/14/2013 | Kerry P Gray | CEO | Buy | 1,000,000 | $0.40 | $400,000.00 | |
| 3/14/2013 | Terrance K Wallberg | CFO | Buy | 100,000 | $0.40 | $40,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ULURU (OTCMKTS:ULUR)
Latest Headlines for ULURU (OTCMKTS:ULUR)
| Source: |
|
ULURU (ULUR) Chart for Friday, July, 21, 2017
